Asia Pacific onychomycosis treatment market will grow by 9.3% annually with a total addressable market cap of $10,998.9 million over 2022-2031, driven by the increasing prevalence of chronic medical ailments, the growing geriatric population, improved therapies and preventative solutions, and the rising healthcare expenditure.
Highlighted with 28 tables and 39 figures, this 93-page report “Asia Pacific Onychomycosis Treatment Market 2021-2031 by Onychomycosis Type (Distal Subungual, White Superficial, Proximal Subungual, Candidal, Others), Treatment Type (Drug Treatment, Laser Therapy, Photodynamic Therapy, Others), Distribution Channel (Hospitals and Clinics, Online Stores, Retail Pharmacies, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific onychomycosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and the Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific onychomycosis treatment market in every aspect of the classification from perspectives of Onychomycosis Type, Treatment Type, Distribution Channel, and Country.
Based on Onychomycosis Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Other Onychomycosis Types
Based on Treatment Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Drug Treatment
• Laser Therapy
• Photodynamic Therapy
• Other Therapies
By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals and Clinics
• Online Stores
• Retail Pharmacies
• Other Distribution Channels
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Onychomycosis Type, Treatment Type and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Bausch Health Companies Inc.
Bayer AG
Cipla Ltd
Dr. Reddys Laboratories Ltd
Galderma SA
GlaxoSmithKline PLC
Johnson & Johnson
Lumenis Ltd
Medimetriks Pharmaceuticals Inc.
Moberg Pharma AB
Novartis AG
Pfizer Inc.
Sanofi SA
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 12
1.2.6 Market Size/Share Estimation 13
1.2.7 Research Limitations 14
1.3 Executive Summary 15
2 Market Overview and Dynamics 17
2.1 Market Size and Forecast 17
2.1.1 Impact of COVID-19 on World Economy 18
2.1.2 Impact of COVID-19 on the Market 20
2.2 Major Growth Drivers 22
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Market by Onychomycosis Type 40
3.1 Market Overview by Onychomycosis Type 40
3.2 Distal Subungual Onychomycosis 42
3.3 White Superficial Onychomycosis 43
3.4 Proximal Subungual Onychomycosis 44
3.5 Candidal Onychomycosis 45
3.6 Other Onychomycosis Types 46
4 Segmentation of Asia Pacific Market by Treatment Type 47
4.1 Market Overview by Treatment Type 47
4.2 Drug Treatment 49
4.3 Laser Therapy 50
4.4 Photodynamic Therapy 51
4.5 Other Therapies 52
5 Segmentation of Asia Pacific Market by Distribution Channel 53
5.1 Market Overview by Distribution Channel 53
5.2 Hospitals and Clinics 55
5.3 Online Stores 56
5.4 Retail Pharmacies 57
5.5 Other Distribution Channels 58
6 Asia-Pacific Market 2021-2031 by Country 59
6.1 Overview of Asia-Pacific Market 59
6.2 Japan 62
6.3 China 65
6.4 Australia 67
6.5 India 69
6.6 South Korea 71
6.7 Rest of APAC Region 73
7 Competitive Landscape 75
7.1 Overview of Key Vendors 75
7.2 New Product Launch, Partnership, Investment, and M&A 78
7.3 Company Profiles 79
Bausch Health Companies Inc. 79
Bayer AG 81
Cipla Ltd 82
Dr. Reddys Laboratories Ltd 83
Galderma SA 84
GlaxoSmithKline PLC 85
Johnson & Johnson 86
Lumenis Ltd 87
Medimetriks Pharmaceuticals Inc. 88
Moberg Pharma AB 89
Novartis AG 90
Pfizer Inc. 91
Sanofi SA 92
RELATED REPORTS 93
List of Tables:
Table 1. Snapshot of Asia Pacific Onychomycosis Treatment Market in Balanced Perspective, 2021-2031 16
Table 2. World Economic Outlook, 2021-2031 19
Table 3. Clinical Trials of Onychomycosis Treatment 25
Table 4. World Health Spending by Region, $ bn, 2013-2020 28
Table 5. Main Product Trends and Market Opportunities in Asia Pacific Onychomycosis Treatment Market 32
Table 6. Asia Pacific Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 40
Table 7. Asia Pacific Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 47
Table 8. Asia Pacific Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 53
Table 9. APAC Onychomycosis Treatment Market by Country, 2021-2031, $ mn 60
Table 10. Japan Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 64
Table 11. Japan Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 64
Table 12. Japan Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 64
Table 13. China Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 66
Table 14. China Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 66
Table 15. China Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 66
Table 16. Australia Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 68
Table 17. Australia Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 68
Table 18. Australia Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 68
Table 19. India Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 70
Table 20. India Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 70
Table 21. India Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 70
Table 22. South Korea Onychomycosis Treatment Market by Onychomycosis Type, 2021-2031, $ mn 72
Table 23. South Korea Onychomycosis Treatment Market by Treatment Type, 2021-2031, $ mn 72
Table 24. South Korea Onychomycosis Treatment Market by Distribution Channel, 2021-2031, $ mn 72
Table 25. Onychomycosis Treatment Market in Rest of APAC by Country/Region, 2021-2031, $ mn 74
Table 26. Bausch Health Companies Inc.: Company Snapshot 79
Table 27. Bausch Health Companies Inc.: Business Segmentation 80
Table 28. Bausch Health Companies Inc.: Product Portfolio 80
